[PDF][PDF] Development of quantification method for GEN-0828, a novel recombinant activated clotting factor Ⅶa candidate drug, and its pharmacokinetic character istics …
YL Liu, XX Zhu, H Gan, Z WU, J LI… - Chin J Pharmacol …, 2021 - cjpt.magtechjournal.com
OBJECTIVE To develop a sensitive method for the detection of GEN-0828 in plasma from
hemophilia model mice and to explore the pharmacokinetic profiles of GEN-0828 in …
hemophilia model mice and to explore the pharmacokinetic profiles of GEN-0828 in …
The Pharmacokinetics and Pharmacodynamics of A Novel Recombinant Activated Human Factor VII, GEN-0828, in Hemophilia B Mice
Y Liu, X Zhu, L Niu, Y Gao, GAN Hui, Z Wu… - Journal of …, 2023 - Elsevier
GEN-0828, a proposed clinical candidate for hemophilia and trauma hemorrhage treatment,
is a novel recombinant activated human factor VII (rFVIIa). The purpose of this paper is to …
is a novel recombinant activated human factor VII (rFVIIa). The purpose of this paper is to …
Kinetic analysis and binding studies of a new recombinant human factor VII a for treatment of haemophilia
J Grandoni, G Perret, C Forier - Haemophilia, 2017 - Wiley Online Library
Introduction/Aim LR 769 is a new second‐generation recombinant human Factor VII a (rh
FVII a) developed for haemophilia treatment. We determined enzymatic properties of LR 769 …
FVII a) developed for haemophilia treatment. We determined enzymatic properties of LR 769 …
Pharmacokinetics, distribution, and excretion of 125I-labeled human plasma-derived-FVIIa and-FX with MC710 (FVIIa/FX mixture) in rats
Y Nakatomi, M Tsuji, T Nakashima, S Gokudan… - Thrombosis research, 2012 - Elsevier
INTRODUCTION: MC710 is a mixture agent consisting of plasma-derived activated factor VII
(FVIIa) and factor X (FX) at a weight ratio of 1: 10 developed as a novel bypassing agent for …
(FVIIa) and factor X (FX) at a weight ratio of 1: 10 developed as a novel bypassing agent for …
Pharmacokinetics and tolerability evaluation of human coagulation recombinant factor VIII (Greengenetm™) in hemophilia a patients
HK Han, KH Shin, SH Paik, JY Chung… - Journal of Korean …, 2011 - snucm.elsevierpure.com
Background: GreenGene™(Green Cross Corp.) is a recombinant clotting factor vii which is
used for hemophilia A. This study aimed to investigate the pharmacokinetics and safety …
used for hemophilia A. This study aimed to investigate the pharmacokinetics and safety …
[HTML][HTML] Pharmacokinetics and pharmacodynamics of SCT800, a new recombinant FVIII, in hemophilia A mice
R Gu, L Liu, L Xie, W Gai, S Cao, Z Meng… - Acta Pharmacologica …, 2016 - nature.com
Aim: SCT800 is a new third-generation recombinant FVIII agent that is undergoing promising
preclinical study. This study aimed to investigate the pharmacokinetic and …
preclinical study. This study aimed to investigate the pharmacokinetic and …
[HTML][HTML] Mod-5014, a Novel Long-Acting FVIIa proposing an improved prophylactic and on demand treatment for hemophilic patients following SC and IV …
G Hart, O Hershkovitz, AB Iilan, M Zakar, L Binder… - Blood, 2013 - Elsevier
Abstract Introduction Prolor Biotech Inc. is a clinical stage public company developing
biobetter long acting versions of existing therapeutic proteins utilizing a technology termed …
biobetter long acting versions of existing therapeutic proteins utilizing a technology termed …
A Phase II clinical trial of a mixture of plasma‐derived factor VII a and factor X (MC 710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and …
A Shirahata, K Fukutake, J Takamatsu, M Shima… - …, 2013 - Wiley Online Library
MC 710, a mixture of plasma‐derived activated factor VII and factor X at a protein weight
ratio of 1: 10, is a novel bypassing agent for haemostasis in haemophilia patients with …
ratio of 1: 10, is a novel bypassing agent for haemostasis in haemophilia patients with …
[HTML][HTML] Novel inhibitor ZED3197 as potential drug candidate in anticoagulation targeting coagulation FXIIIa (F13a)
R Pasternack, C Büchold, R Jähnig, C Pelzer… - Journal of Thrombosis …, 2020 - Elsevier
Abstract Background Factor XIII (FXIII) is the final enzyme of the coagulation cascade. While
the other enzymatic coagulation factors are proteases, FXIII belongs to the transglutaminase …
the other enzymatic coagulation factors are proteases, FXIII belongs to the transglutaminase …
Cloning and expression of rat coagulation factor VII
S Seetharam, K Murphy, C Atkins, G Feuerstein - Thrombosis research, 2003 - Elsevier
Smaller and widely available animals such as rats are commonly used to evaluate
antithrombotic drug candidates in vivo. However, the isolation and purification of FVII from …
antithrombotic drug candidates in vivo. However, the isolation and purification of FVII from …